Loading stock data…
GLUE
$20.26+0.87 (+4.49%)
Market ClosedLast close May 11
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Monte Rosa Therapeutics, Inc. in the Healthcare sector is trading at $20.26. The stock is currently 21% below its 52-week high of $25.77, remaining 44.4% above its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why GLUE maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$20.26
Potential Upside
5%
Whystock Fair Value$21.27
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The comp...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.64
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.41%
Volume
Today's trading volume
971,955
Recent News
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention
Monte Rosa Therapeutics, NasdaqGS: GLUE, reported positive interim clinical results for several molecular glue degrader programs. The company plans to start multiple Phase 2 studies for MRT-8102 in cardiovascular risk patients and MRT-2359 in metastatic prostate cancer in the upcoming year. The updates come as the stock trades at $19.81, with strong recent share price performance. For investors watching Monte Rosa Therapeutics, NasdaqGS: GLUE, the new data arrives after a strong run in the...
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -58.84% and -80.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
This biotech focused on precision medicines for cancer and immune disorders disclosed a notable insider sale after a strong year for shares.
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story
Monte Rosa Therapeutics (NasdaqGS:GLUE) announced a new supply agreement with Johnson & Johnson to evaluate MRT-2359 with ERLEADA in metastatic castration resistant prostate cancer. The company is initiating a Phase 2 trial of the MRT-2359 plus ERLEADA combination in this setting. Additional positive clinical data for MRT-2359 in advanced prostate cancer were presented at ASCO GU 2026. Monte Rosa Therapeutics enters this news cycle with its shares at $15.63 and a 1 year return of 169.5%...